Serveur d'exploration Tocilizumab - Analysis (2020)

Index « Titre (en) » - entrée « tocilizumab »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
tnf < tocilizumab < tofacitinib  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 103.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000011 (2020) Binqing Fu ; Xiaoling Xu ; Haiming WeiWhy tocilizumab could be an effective treatment for severe COVID-19?
000012 (2020) Seoyoung C. Kim [États-Unis] ; Sebastian Schneeweiss [États-Unis]When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety.
000016 (2020) M. SilbersteinVitamin D: A simpler alternative to tocilizumab for trial in COVID-19?
000019 (2020) Martin Michaud [France] ; Florian Catros [France] ; Francis Gaches [France]Usefulness of serum amyloid a protein dosage for monitoring patients receiving tocilizumab.
000020 (2020) Jared Radbel [États-Unis] ; Navaneeth Narayanan [États-Unis] ; Pinki J. Bhatt [États-Unis]Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report.
000026 (2020) M. Moriyama [Japon] ; Y. Wada [Japon] ; T. Minamoto [Japon] ; M. Kondo [Japon] ; M. Honda [Japon] ; Y. Murakawa [Japon]Unexpectedly lower proportion of placental transferred tocilizumab relative to whole immunoglobulin G: a case report.
000031 (2020) Jerome Razanamahery [France] ; Sebastien Humbert [France] ; Helder Gil [France] ; Kevin Bouiller [France] ; Nadine Magy-Bertrand [France]Tropheryma Whipplei infection mimicking giant cell arteritis flare in a patient treated with interleukin-6 receptor blocker tocilizumab.
000036 (2020) B P Hibler [États-Unis] ; A. Markova [États-Unis]Treatment of severe cutaneous adverse reaction with tocilizumab.
000043 (2020) Joana Rodrigues [Oman] ; Daniela Santos-Faria ; Joana Silva ; Soraia Azevedo ; Francisca Guimarães ; Diogo Esperança Almeida ; Filipa Teixeira ; Daniela Peixoto ; Sérgio Alcino ; Carmo Afonso ; José Tavares-CostaTreating Adult-Onset Still Disease With Tocilizumab: A Case-Based Review.
000049 (2020) Yeimer Ortiz-Martínez [Colombie]Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19.
000050 (2020) Daichi Fukaya [Japon] ; Tsutomu Inoue [Japon] ; Yuta Kogure [Japon] ; Hiroshi Kajiyama [Japon] ; Keisuke Ishizawa [Japon] ; Takeru Seto [Japon] ; Hajime Hasegawa [Japon] ; Toshihide Mimura [Japon] ; Hirokazu Okada [Japon]Tocilizumab-induced immunocomplex glomerulonephritis: a report of two cases.
000051 (2020) Eun Hye Park [Corée du Sud] ; Eun Young Lee [Corée du Sud] ; Kichul Shin [Corée du Sud] ; Hyoun-Ah Kim [Corée du Sud]Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review.
000052 (2020) Yasuhiko Hirabayashi [Japon]Tocilizumab, an anti-interleukin-6 receptor antibody, efficiently ameliorates persistent joint inflammation in rheumatoid arthritis.
000053 (2020) Jean-Marie Michot [France] ; Laurence Albiges [France] ; Nathalie Chaput [France] ; Veronique Saada [France] ; Fanny Pommeret [France] ; Franck Griscelli [France] ; Corinne Balleyguier [France] ; Benjamin Besse [France] ; Aurélien Marabelle [France] ; Florence Netzer [France] ; Mansouria Merad [France] ; Caroline Robert [France] ; Fabrice Barlesi [France] ; Bertrand Gachot [France] ; Annabelle Stoclin [France]Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report
000054 (2020) Rongda Li [République populaire de Chine] ; Qi Wan [République populaire de Chine] ; Pan Chen [République populaire de Chine] ; Shufen Mao [République populaire de Chine] ; Qiuju Wang [République populaire de Chine] ; Xiaoxin Li [République populaire de Chine] ; Yi Yang [République populaire de Chine] ; Li Dong [République populaire de Chine]Tocilizumab treatment in Felty's syndrome.
000055 (2020) Pan Luo [République populaire de Chine] ; Yi Liu [République populaire de Chine] ; Lin Qiu [République populaire de Chine] ; Xiulan Liu [République populaire de Chine] ; Dong Liu [République populaire de Chine] ; Juan Li [République populaire de Chine]Tocilizumab treatment in COVID-19: A single center experience.
000056 (2020) Martin Krusche [Allemagne] ; Nikolas Ruffer [Allemagne] ; Udo Schneider [Allemagne] ; Marco Meyer [Allemagne] ; Gerd Burmester [Allemagne] ; Ina Kötter [Allemagne]Tocilizumab treatment for polyarteritis nodosa.
000057 (2020) Lili Pan [République populaire de Chine] ; Juan Du [République populaire de Chine] ; Jiayi Liu [République populaire de Chine] ; Hua Liao [République populaire de Chine] ; Xiaoli Liu [République populaire de Chine] ; Xi Guo [République populaire de Chine] ; Jing Liang [République populaire de Chine] ; Hongya Han [République populaire de Chine] ; Lixia Yang [République populaire de Chine] ; Yujie Zhou [République populaire de Chine]Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis.
000058 (2020) Masaki Shimizu [Japon] ; Mao Mizuta [Japon] ; Nami Okamoto [Japon] ; Takahiro Yasumi [Japon] ; Naomi Iwata [Japon] ; Hiroaki Umebayashi [Japon] ; Yuka Okura [Japon] ; Noriko Kinjo [Japon] ; Tomohiro Kubota [Japon] ; Yasuo Nakagishi [Japon] ; Kenichi Nishimura [Japon] ; Mariko Mohri [Japon] ; Masato Yashiro [Japon] ; Junko Yasumura [Japon] ; Hiroyuki Wakiguchi [Japon] ; Masaaki Mori [Japon]Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
000059 (2020) Banafsheh Mosharmovahed [Iran] ; Yousef Fatahi [Iran] ; Bahareh Mohebbi [Iran] ; Sohrab Ali Ghorbanian [Iran] ; Sara Assadiasl [Iran]Tocilizumab in transplantation.
000060 (2020) Augustin Latourte [France] ; Hang-Korng Ea [France] ; Aline Frazier [France] ; Anne Blanchard [France] ; Frédéric Lioté [France] ; Hubert Marotte [France] ; Thomas Bardin [France] ; Pascal Richette [France]Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/Title.i -k "tocilizumab" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/Title.i  \
                -Sk "tocilizumab" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    Title.i
   |clé=    tocilizumab
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021